Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
OncoSec Medical's Sloan Ratio for the quarter that ended in Jan. 2023 was 0.00%.
As of Jan. 2023, OncoSec Medical has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
OncoSec Medical Sloan Ratio % Historical Data
The historical data trend for OncoSec Medical's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of OncoSec Medical's Sloan Ratio %
For the Biotechnology subindustry, OncoSec Medical's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoSec Medical's Sloan Ratio % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoSec Medical's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where OncoSec Medical's Sloan Ratio % falls into.
OncoSec Medical Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
OncoSec Medical's Sloan Ratio for the fiscal year that ended in Jul. 2022 is calculated as
OncoSec Medical's Net Income for the trailing twelve months (TTM) ended in Jan. 2023 was -6.247 (Apr. 2022 ) + -8.216 (Jul. 2022 ) + -8.061 (Oct. 2022 ) + -6.861 (Jan. 2023 ) = $-29.39 Mil.
OncoSec Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jan. 2023 was -5.341 (Apr. 2022 ) + -6.916 (Jul. 2022 ) + -6.127 (Oct. 2022 ) + -6.611 (Jan. 2023 ) = $-25.00 Mil.
OncoSec Medical's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jan. 2023 was 0 (Apr. 2022 ) + 0 (Jul. 2022 ) + 0 (Oct. 2022 ) + 0 (Jan. 2023 ) = $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoSec Medical (OTCPK:ONCSQ) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jan. 2023, OncoSec Medical has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
OncoSec Medical Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of OncoSec Medical's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
OncoSec Medical (OncoSec Medical) Business Description
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ONCSQ has been successfully added to your 